Adenocarcinoma of the Ovaries (DBCOND0038690)

Identifiers

Synonyms

Adenocarcinoma Ovary / Ovarian Adenocarcinoma / Ovary Adenocarcinoma / Adenocarcinoma of the Ovary / Ovarian epithelial cancer / Ovarian epithelial cancer NOS

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cyclophosphamide	A nitrogen mustard used to treat lymphomas, myelomas, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma.	DNAtarget Cytochrome P450 2B6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A4enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2A6enzyme Cytochrome P450 2C18enzyme Cytochrome P450 2C8enzyme Cytochrome P450 3A5enzyme Nuclear receptor subfamily 1 group I member 2target
Thiotepa	An alkylating agent used to prevent graft rejection in stem cell transplantation and to treat a variety of malignancies including certain types of adenocarcinoma and superficial bladder carcinomas.	Cytochrome P450 2B6enzyme Cytochrome P450 3A4enzyme DNAtarget Cholinesteraseenzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05538624	A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary	AVB-001	treatment	1 / 2	terminated
NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Ipilimumab Nivolumab	treatment	2	active_not_recruiting
NCT03641287	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	No drug interventions	supportive_care	Not Available	terminated
NCT00899093	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy	No drug interventions	Not Available	Not Available	terminated
NCT02217956	Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma	Bevacizumab Cisplatin	treatment	1	completed
NCT02923739	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Emactuzumab Paclitaxel	treatment	2	terminated
NCT05001282	A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	No drug interventions	treatment	1 / 2	terminated
NCT04248231	CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma	No drug interventions	Not Available	Not Available	completed
NCT03365791	PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies	Ieramilimab Spartalizumab	treatment	2	completed
NCT05451849	A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT00585845	Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment	CRS-207 Listeria monocytogenes	treatment	1	terminated
NCT03608618	Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma	Cyclophosphamide	treatment	1	terminated
NCT00660101	Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer	DNP-Modified autologous tumor vaccine	treatment	1 / 2	unknown_status